RT Journal Article
SR Electronic
T1 Longitudinal analyses reveal age-specific immune correlates of COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.25.21250189
DO 10.1101/2021.01.25.21250189
A1 Sloan A. Lewis
A1 Suhas Sureshchandra
A1 Michael Z. Zulu
A1 Brianna Doratt
A1 Amanda Pinski
A1 Micaila Curtis
A1 Allen Jankeel
A1 Izabela Ibraim
A1 Nicholas Rhoades
A1 Xiwen Jiang
A1 Delia Tifrea
A1 Frank Zaldivar
A1 Weining Shen
A1 Robert Edwards
A1 Daniel Chow
A1 Dan Cooper
A1 Alpesh Amin
A1 Ilhem Messaoudi
YR 2021
UL http://medrxiv.org/content/early/2021/01/30/2021.01.25.21250189.abstract
AB Severe COVID-19 disproportionately impacts older individuals and those with comorbidities. It is estimated that approximately 80% of COVID-19 deaths are observed among individuals >65 years of age. However, the immunological underpinnings of severe COVID-19 in the aged have yet to be defined. This study captures the longitudinal immune response to SARS-CoV-2 infection in a cohort of young and aged patients with varying disease severity. Phenotypic transcriptional and functional examination of the peripheral mononuclear cells revealed age-, time, and disease severity-specific adaptations. Gene expression signatures within memory B cells suggest qualitative differences in the antibody responses in aged patients with severe disease. Examination of T cells showed profound lymphopenia, that worsened over time and correlated with lower levels of plasma cytokines important for T cell survival in aged patients with severe disease. Single cell RNA sequencing revealed augmented signatures of activation, exhaustion, cytotoxicity, and type-I interferon signaling in memory T cells and NK cells. Although hallmarks of a cytokine storm were evident in both groups, older individuals exhibited elevated levels of chemokines that mobilize inflammatory myeloid cells, notably in those who succumbed to disease. Correspondingly, we observed a re-distribution of DC and monocytes with severe disease that was accompanied by a rewiring towards a more regulatory phenotype. Several of these critical changes, such as the reduction of surface HLA-DR on myeloid cells, were reversed in young but not aged patients over time. In summary, the data presented here provide novel insights into the impact of aging on the host response to SARS-CoV2 infection.Competing Interest StatementAlpesh Amin reported serving as PI or co-I of clinical trials sponsored by NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, OctaPharma, Fulcrum Therapeutics, Alexion. He has served as speaker or consultant for BMS, Pfizer, BI, Portola, Sunovion, Mylan/Theravance, Salix, Alexion, AstraZeneca, Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achogen LaJolla, Millenium, Ferring, PeraHealth, HeartRite, Aseptiscope, Sprightly.Funding StatementThis study was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR001414. S.A.L is supported by NIH F31 A028704. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by University of California Irvine Institutional Review Boards. Informed consent was obtained from all enrolled subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets supporting the conclusions of this article are available on NCBIs Sequence Read Archive (SRA number pending).